JOIN NOW!
NEW!
FAQs
Describe the TYK2/STAT Signaling Pathway and Immunologic Rationale for TYK2 Directed Therapy For The Treatment of Psoriasis and Psoriatic Arthritis.
​
How Does the Selectivity of TYK2 and JAK Enzyme Inhibition Influence Their Safety Profiles
What Is Minimal Disease Activity in PsA and How Does Deucravacitinib Perform at 52 Weeks?
​​
TYK2/STAT Signaling: The Immunologic Rationale for TYK2 Therapy in SLE & Sjögren’s Disease
MEDICATION REVIEWS
What Is the Mechanism of Action of Deucravacitinib?
What is the Safety Profile of Deucravactinib in PsO and PsA?​​
JOURNAL CLUBS
A Review of the Safety and Efficacy of Deucravacitinib or Plaque Psoriasis: an Expert Consensus Panel
PODCASTS
Understanding The TYK2/STAT Signaling Pathway in PsA: Clinical Implications and Beyond
Foundations of PMR: Diagnosis, First-Line Therapy, and Tapering Strategies
